Blood and Plasma Collection For Use in Future Clinical Trials

There is a concern that the influenza virus will become resistant to the standard of care,
oseltamivir (commonly known as Tamiflu), as resistance to this medication has been observed
in people infected with the seasonal influenza virus. Because of the possibility of drug
resistance, additional treatment options for influenza are needed. The purpose of this study
is to collect blood from people who have recovered from influenza or who have received a
seasonal influenza vaccine. The blood will then be processed into Food and Drug
Administration (FDA)-licensed fresh frozen plasma (FFP). In a future clinical trial, this
plasma will be used as a treatment for people hospitalized with influenza.

This study will enroll people who have recovered from influenza or received a seasonal
influenza vaccine. Participants will donate blood at FDA-licensed blood donor centers up to
three times during the 240-day study period.

Inclusion Criteria:

- Currently healthy males 18 - 59 years of age with a history suggestive of having
anti-influenza antibodies (either or both of the following):

1. An influenza-like illness (e.g., fever, chills, malaise, cough, myalgias,
nausea). Subjects must asymptomatic and must be afebrile for ≥ 7 days, and must
enroll within 12 months of onset of illness.

2. Vaccinated with a licensed influenza vaccine. Enrollment must occur >14 days and
< 12 months from date of vaccination.

- Must be an adult male Department of Defense (DoD)/beneficiary

- Sign informed consent and Health Insurance Portability and Accountability Act (HIPAA)
document

- A demonstrated H1N1 HAI titer of 1:160 or greater and H3N2 HAI titer of 1:40 or
greater.

- Must also meet all Standard-of-Care inclusion criteria for donation of blood or plasma
at the FDA-licensed donor center prior to every donation session. More information on
this criterion can be found in the protocol.

Exclusion Criteria:

- Donors that do not meet all Standard-of-Care FDA approved requirements for the
donation of blood and production of FFP as determined by the FDA-licensed donor center
prior to every donation session may be excluded from further participation in this
study. Study exclusion will be determined by the principal investigator (PI) or lead
investigator at the study site.

- Donors that fail the Standard-of-Care screening and Blood Borne Pathogen screening for
the following blood borne pathogens at the donor center will be excluded:

1. Anti-HIV-I/II

2. Anti-human T-lymphotropic virus (HTLV)-I/II

3. Anti-hepatitis C (HCV)

4. Anti-hepatitis B core antigen (HBc)

5. Anti-T. cruzi (enzyme immunoassay [EIA] for Chagas disease) (if required by the
FDA-licensed donor center or becomes a nationwide FDA requirement)

6. Hepatitis B surface antigen (HBsAg)

7. Serologic test for syphilis

8. HIV nucleic acid test (NAT)

9. HCV NAT

10. West Nile virus (WNV) NAT

- Participation in other medical research that includes:

1. Studies that are currently ongoing or will start during the duration of this
study that require more than 60 mL of blood to be donated in any 56-day period of
time

2. Administration of any unlicensed drug in the 3 months before study entry or
during the duration of this study

3. Administration of any unlicensed vaccine in the 12 months before study entry or
during the duration of this study, with the exception of unlicensed influenza
vaccine